Meta-analyses of randomized trials assessing the effect of neoadjuvant chemotherapy in locally advanced gastric cancer.

Li, H.; Zhu, Fengqin; Cao, Yuqin; Zhai, Limin; Lin, Tian

doi:10.1200/jco.2010.28.15_suppl.4042

Cited by 8 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No additional relevant studies were identified in a search of the Cochrane Library. Overall, 22 RCTs , 13 meta-analyses [34][35][36][37][38][39][40][41][42][43][44][45][46], and two secondary analyses that report survival data [47,48] are included in this systematic review (see Fig. 1).…”

Section: Literature Search Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America

Knight

Earle²,

Cosby

et al. 2012

Gastric Cancer

View full text Add to dashboard Cite

Section: Literature Search Resultsmentioning

confidence: 99%

“…Two meta-analyses were identified that compared preoperative chemotherapy versus surgery alone [42,43]. Both of these meta-analyses were available only in abstract form, providing only a limited amount of methodological information, and for this reason will not be discussed further.…”

Section: Preoperative or Perioperative Chemotherapymentioning

confidence: 99%

Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America

Knight

Earle²,

Cosby

et al. 2012

Gastric Cancer

View full text Add to dashboard Cite

“…Two recent meta-analyses examined the role of neoadjuvant chemotherapy. In the first, a reduction in absolute risk of death at 5 years of 32% was observed in favor of neoadjuvant treatment (53). In the second, the decrease in risk of death at 5 years was lower (only 18%) at the expense of patients with tumors at the esophagogastric junction treated with preoperative therapy (54).…”

Section: Perioperative Treatmentmentioning

confidence: 98%

Current management of gastric cancer

Viúdez-Berral

Miranda-Murua

Arias-de-la-Vega

et al. 2012

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Gastric cancer is a disease with high incidence and mortality in our population. The prognosis of patients with this disease is closely related to the neoplasm stage at diagnosis, including the following characteristics of the tumor: extension into the gastric wall thickness, spread to locoregional lymph nodes and the ability to generate distant metastases, as described by the TNM classification. For localized tumors characterized only by invasion of mucosa or submucosa at diagnosis, survival at 5 years is between 70 and 95% with exclusive surgical management; however, when extension into the gastric wall is higher and/or there is locoregional nodal involvement, survival decreases to 20-30% at 5 years. Currently, at high-volume centers, the extent of gastrectomy is individualized based on several parameters, which in an increasing number of cases allows a total gastrectomy with D2 lymphadenectomy and preservation of the spleen and pancreas. This improved procedure increases the chance of R0 surgery and improves the relationship between resected and affected lymph nodes, resulting in a decreased risk of the long-term locoregional recurrence. To improve these results, different therapeutic strategies combining chemotherapy or chemoradiotherapy with surgery have been tested. Previously, the Intergroup 0116 clinical trial, published in 2001, which changed clinical practice in the United States, showed that adjuvant chemoradiotherapy improved survival (from 26 to 37 months overall survival) of these patients. In Europe, perioperative chemotherapy has been considered the standard treatment, since the publication of two randomized phase III trials showed an increase at 5 years survival in the group treated with chemotherapy.

show abstract

“…In summary, perioperative chemotherapy superiority when compared to isolated surgery has been confirmed in solid studies and with a well-designed methodology. There are no differences in length of stay, rates of complications and operative mortality, and there seems to be an improvement in the histopathological tumor evaluation 15 . Among the many perioperative chemotherapy studies in progress, the results of the FLOT4 trial, which confronts the ECF schemes using docetaxel with 5-Fu and oxaliplatin are pending.…”

Section: Resultsmentioning

confidence: 96%

Current Status of the Multidisciplinary Treatment of Gastric Adenocarcinoma

Toneto

Viola

2018

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

Background: The complexity of the management of gastric cancer requires a multidisciplinary evaluation of patients with this tumor. Several treatments have been employed, associated to the surgical resection. Objective: To review the available therapeutic alternatives for the treatment of gastric adenocarcinoma. Methods : A review of selected articles on multidisciplinary treatment of gastric adenocarcinoma in the Pubmed and Medline databases between 2000 and 2017 was carried out. The following headings were related: stomach cancer, treatment, chemotherapy and radiotherapy. Results : There are several valid alternatives, with good results for the treatment of gastric cancer: chemoradiotherapy or chemotherapy in the adjuvant scenario; perioperative chemotherapy; and chemoradiotherapy after neoadjuvance with isolated chemotherapy. Conclusion : Current evidences suggest that combined multidisciplinary treatment is superior to surgery alone. However, the optimal treatment regimen is not yet established, and depends on a number of factors, especially the type of surgical resection employed. Therefore, the therapeutic decision should be made by a multidisciplinary team, assessing patient’s personal characteristics, biology of the tumor, residual disease, risks and side effects.

show abstract

Meta-analyses of randomized trials assessing the effect of neoadjuvant chemotherapy in locally advanced gastric cancer.

Cited by 8 publications

References 0 publications

Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America

Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America

Current management of gastric cancer

Current Status of the Multidisciplinary Treatment of Gastric Adenocarcinoma

Contact Info

Product

Resources

About